Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05497804 · ClinicalTrials.gov registry record · Phase 2

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

A Phase 2 study of Multiple Myeloma and ISS Stage III Plasma Cell Myeloma, sponsored by Mayo Clinic.

Active
Registry status
Phase 2
Development phase
17
Enrollment target
3
Study locations

NCT05497804 is a Phase 2 study of Multiple Myeloma and ISS Stage III Plasma Cell Myeloma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 17 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05497804, a Phase 2 study of Multiple Myeloma and ISS Stage III Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
17 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.

Conditions Studied

Multiple Myeloma ISS Stage III Plasma Cell Myeloma

Interventions

  • PROCEDURE Computed Tomography
  • DRUG Dexamethasone
  • BIOLOGICAL Daratumumab
  • PROCEDURE Bone Marrow Aspiration and Biopsy
  • DRUG Carfilzomib

Study Locations (3)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2022-09-22
Est. Completion 2028-11-20
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05497804

The ClinicalTrials.gov registry entry for NCT05497804 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT05497804 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05497804 about?

NCT05497804 is a clinical study titled "Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial". This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killi...

What is the current status of trial NCT05497804?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2022-09-22. Estimated completion is 2028-11-20.

What conditions does trial NCT05497804 study?

This clinical trial studies the following conditions: Multiple Myeloma, ISS Stage III Plasma Cell Myeloma.

What interventions are being tested in trial NCT05497804?

The interventions under investigation include: Computed Tomography (PROCEDURE), Dexamethasone (DRUG), Daratumumab (BIOLOGICAL), Bone Marrow Aspiration and Biopsy (PROCEDURE), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT05497804?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05497804 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

ISS Stage III Plasma Cell Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.